Results 211 to 220 of about 138,831 (302)

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Efficient generation of human dorsal spinal GABAergic progenitors for the treatment of spinal cord injury. [PDF]

open access: yesExp Mol Med
Feng X   +17 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

RVLM C1 Neurons Innervate Sacral as well as Thoracolumbar Autonomic Preganglionic Neurons in the Rat. [PDF]

open access: yesJ Comp Neurol
Llewellyn-Smith IJ   +5 more
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić   +7 more
wiley   +1 more source

The effectiveness of basivertebral nerve radiofrequency ablation for the treatment of vertebrogenic low back pain: 1-year results of a prospective real-world cohort study. [PDF]

open access: yesPain Med
McCormick ZL   +14 more
europepmc   +1 more source

Effect of oxycodone vs. morphine as first‐line opioid on new persistent opioid use after orthopaedic surgery: A prospective sequential cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background Postoperative opioids, intended for short‐term analgesia, contribute to new persistent opioid use in 1%–7% of patients, adversely affecting outcomes. Oxycodone may carry higher risk than morphine, though long‐term data are limited.
Eward J. Melis   +5 more
wiley   +1 more source

New opportunities for bioscaffold‐enabled spinal cord injury repair

open access: yesBMEMat, EarlyView.
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy